Roivant swings to $265.9 million Q3 net loss; revenue falls to $2.0 million
Roivant reported a net loss attributable to Roivant Sciences Ltd. of $265.9 million, or $0.38 per share, for the quarter ended December 31, 2025, compared with net income of $169.4 million a year earlier. The prior-year result included a $327.0 million gain from discontinued operations tied to the Dermavant sale, and the loss from continuing operations rose to $313.7 million from $208.9 million, so shareholders face a larger operating loss even as the company reported positive Phase 2 brepocitinib data in cutaneous sarcoidosis.
Key points
- Revenue was $2.0 million for the quarter, down from $9.0 million a year earlier
- Loss from continuing operations was $0.38 per share, compared with $0.22 per share a year earlier
- R&D expenses rose $23.8 million to $165.4 million; G&A rose $33.5 million to $175.1 million, including a $17.1 million headquarters impairment
- Consolidated cash, cash equivalents, restricted cash and marketable securities totaled $4.5 billion as of December 31, 2025
The filing
Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.